Food head at FDA quits citing Trump administration's mass staff cuts
Jim Jones, who joined the agency in September 2023, cited 'indiscriminate' layoffs to 89 staff members, including key technical experts. In his resignation letter to the acting FDA commissioner, Sara Brenner, seen by Bloomberg News, Jones said the cuts would make it 'fruitless' to continue in his role given the Trump administration's 'disdain for the very people' needed to implement food safety reforms.
'I was looking forward to working to pursue the department's agenda of improving the health of Americans by reducing diet-related chronic disease and risks from chemicals in food,' Jones wrote.
Some of those recent efforts include the January banning of controversial food dye Red No 3, a bright-red color additive that was found to cause cancer in male lab rats.
Specialists in nutrition, infant formula and food-safety response, including 10 staff members responsible for reviewing potentially unsafe food ingredients, were targets of layoffs, according to the letter.
The FDA did not respond to a request for comment.
The White House defended the staff changes, with press secretary Karoline Leavitt telling Bloomberg some 'bureaucrats' were resistant to implementing the president's agenda.
'President [Donald] Trump is only interested in the best and most qualified people who are also willing to implement his America First Agenda on behalf of the American people,' Leavitt said in an email. 'It's not for everyone, and that's okay.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
a few seconds ago
- The Independent
Breakthrough study finds it takes 3.5 years to diagnose dementia after first symptoms
It takes an average of 3.5 years to diagnose patients with dementia following their first symptoms, according to researchers. Early diagnosis and intervention is crucial in managing symptoms of dementia and developing an effective treatment course. However, experts fear that delays in vital treatment may occur due to confusion over symptoms, stigma and inconsistent approaches by medical professionals, among other things. Dementia is a condition that impacts's a person's thinking, memory, and behavior. Alzheimer's disease is the most common form of dementia, and more than 6 million Americans are affected by the progressive brain disorder. Symptoms include issues with memory, attention, communication, and vision problems. 'Timely diagnosis of dementia remains a major global challenge, shaped by a complex set of factors, and specific healthcare strategies are urgently needed to improve it. Other studies estimate that only 50 to 65 percent of cases are ever diagnosed in high-income countries, with many countries having even lower diagnostic rates,' Dr. Vasiliki Orgeta, an associate professor at University College London's Division of Psychiatry, said in a statement. U.K. researchers announced this week that it takes an average of more than three years to diagnose people with dementia following their first symptoms. But, early diagnosis is crucial to improve their quality of life later on (AFP via Getty Images) 'Timely diagnosis can improve access to treatments and for some people prolong the time living with mild dementia before symptoms worsen,' she added. The university's researchers also found that, for some, that diagnosis time may be even longer. For patients with early-onset dementia, it may take as long as four years. Early-onset dementia refers to dementia in someone younger than age 65. Those with frontotemporal dementia, the most common form for those under 60, are also were 'consistently associated with a longer interval to diagnosis.' The conclusions were the result of an analysis of 13 previously published international studies that reported data on 30,257 participants. The studies included medical records and interviews of patients or family members. Notably, while data on racial disparities was limited, one of the studies reviewed found that Black patients tended to experience a longer delay before diagnosis. Alzheimer's disease is the most common form of dementia. Nearly seven million Americans are affected by the progressive brain disorder (Getty Images) The authors noted that missed symptoms mistaken for aging, limited access to specialist care, language differences, and low public awareness could have an impact on diagnosis time. Orgeta said that their work highlights 'the need for clear conceptual framework on time to diagnosis in dementia.' 'To speed up dementia diagnosis, we need action on multiple fronts. Public awareness campaigns can help improve understanding of early symptoms and reduce stigma, encouraging people to seek help sooner,' she said. 'Clinician training is critical to improve early recognition and referral, along with access to early intervention and individualised support so that people with dementia and their families can get the help they need.' A test has recently been developed that scientists say could predict dementia up to nine years before diagnosis, with 80 percent accuracy. The study is the first systematic review and meta-analysis of global evidence examining time to diagnosis in dementia. It was published this week in the International Journal of Geriatric Psychiatry .
Reuters
a minute ago
- Reuters
American Kratom Association Praises Secretary Kennedy and Commissioner Makary for Bold Action to Recommend Scheduling of Dangerous 7-OH Products
WASHINGTON, DC, July 29, 2025 (EZ Newswire) -- American Kratom Association (AKA), opens new tab today applauded Secretary Robert Kennedy and FDA Commissioner Dr. Marty Makary for their decisive and science-driven recommendation to classify 7-hydroxymitragynine (7-OH) as a Schedule I substance under the federal Controlled Substances Act. This bold step is a critical milestone in protecting public health and consumer safety from dangerous synthetic products that masquerade as natural kratom. 'Secretary Kennedy and Commissioner Makary have shown exceptional leadership in confronting one of the most urgent public health threats related to mislabeled, manipulated psychoactive substances,' said Mac Haddow, senior fellow on public policy for the American Kratom Association. 'These 7-OH products are not kratom. They are chemically altered substances that carry potent opioid-like effects and pose an imminent threat to consumers. This move sends a clear and long-overdue message: the safety of the American public comes first.' 7-hydroxymitragynine is a metabolite — not a naturally occurring substance in the kratom plant — and occurs during the drying of kratom leaves at extremely low levels, typically less than 0.01%. However, unscrupulous manufacturers have exploited chemical manipulation to create concentrated 7-OH products that far exceed natural levels, creating high-potency, opioid-like effects that are addictive and potentially lethal. These products are often falsely marketed under the kratom name, misleading consumers and damaging the reputation of natural kratom, which has a vastly different safety profile. The American Kratom Association has worked tirelessly to educate policymakers, regulators, and the public on the difference between natural kratom products and chemically manipulated 7-OH formulations. The AKA has advocated for state-based Kratom Consumer Protection Acts (KCPA) to ban the sale of adulterated and dangerously enhanced products. This federal scheduling recommendation is a landmark development that supports those efforts and establishes a much-needed national framework to protect consumers. 'The FDA's own research shows that natural kratom has a relatively low potential for abuse and may offer harm-reduction benefits when used responsibly,' Haddow continued. 'It is the synthetic manipulation of 7-OH that has created the danger. The action by Secretary Kennedy and Commissioner Makary is not only scientifically justified, it is morally imperative.' The AKA urges swift action by the Drug Enforcement Administration (DEA) to initiate the rule-making process to schedule synthetically manipulated 7-hydroxymitragynine and to make clear that such action does not impact the legal status of natural kratom or its primary alkaloids, mitragynine and unaltered 7-OH occurring within the plant matrix. The goal is to eliminate the threat posed by rogue products while preserving access to safe, regulated kratom. 'We look forward to working with federal agencies and state policymakers to ensure that safe access to natural kratom is protected, while these dangerous imposters are removed from the marketplace,' said Haddow. Note: The FDA also released "Hiding in Plain Sight: 7-OH Products, opens new tab" to help educate the public. About American Kratom Association (AKA) American Kratom Association (AKA) is a consumer-based, nonprofit organization, focused on furthering the latest science as guidance for kratom public policy. AKA works to give a voice to millions of Americans by fighting to protect their rights to access safe and natural kratom. For more information, visit and learn more at Media Contact Mac Haddowpress@ ### SOURCE: American Kratom Association (AKA) Copyright 2025 EZ Newswire See release on EZ Newswire
Reuters
an hour ago
- Reuters
FDA recommends 7-OH compound found in vapes be controlled
WASHINGTON, July 29 (Reuters) - The U.S. Food and Drug administration is recommending the scheduling of the 7-OH compound as a controlled substance because of its opioid properties, FDA Commissioner Marty Makary said on Tuesday. Many products containing 7-OH are available in vape stores and the compound is present in drinks and children's gummies, he said at a news conference. The FDA letter to the Drug Enforcement Administration will recommend scheduling 7-OH above a concentration threshold as a Class 1 controlled substance. The substance 7-OH is increasingly recognized as having potential for abuse because of its ability to bind to opioid receptors, the FDA said. "Yet it is sold in vape stores, in smoke shops, and convenience stores, and gas stations, that are popping up all over the United States," Makary said. The FDA is issuing a report explaining the risks of the synthetic substance, made from the kratom plant, and sending a letter to every physician in the United States warning them about the substance. "We're going to continue to try to educate the public," Makary said.
